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Abstract
Background: Intensive inpatient lifestyle treatment may be a suitable alternative for severely obese children and
adolescents who do not benefit from ambulatory obesity treatment.
The aim was to evaluate the effectiveness of two intensive one-year lifestyle treatments with varying inpatient
periods for severely obese children and adolescents with regard to SDS-BMI and cardiometabolic risk factors.
Methods: The study was designed as a randomized controlled trial with two active treatment groups.
Eighty participants (8–19 years) with severe obesity received treatment at a specialized childhood obesity center in
the Netherlands. Severe obesity was defined as a SDS-BMI ≥ 3.0 or a SDS-BMI ≥ 2.3 in combination with obesity-
related comorbidity.
Participants received an intensive one-year lifestyle treatment with an inpatient period of either two months and
biweekly return visits during the next four months (short-stay group) or six months (long-stay group), both followed
by six monthly return visits.
Outcomes were assessed at baseline, six and 12 months and included SDS-BMI as primary outcome and
cardiometabolic risk factors such as SDS-waist circumference, systolic- and diastolic blood pressure, and blood
measurements as secondary outcomes.
To evaluate differences in the course of the primary- and secondary outcomes over time between the two
treatment groups, Generalized Estimating Equations (GEE) were performed.
Results: No differences in the course of SDS-BMI or secondary outcomes over time were found between the two
treatment groups after one year of treatment. SDS-BMI decreased statistically significantly after one year of
treatment compared with baseline in both groups (0.33 (0.48) in the short-stay and 0.52 (0.49) in the long-stay
group). Similar results were found for SDS-waist circumference, diastolic blood pressure and HDL-cholesterol.
Conclusions: Since there were no significant differences in effects between the short- and long-stay treatment and
considering the burden of the long-stay treatment for children and families, we recommend implementation of the
short-stay treatment.
Trial registration: Netherlands Trial Register NTR1678, registered 20-Feb-2009
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Background
During the last few decades, the prevalence of (severe)
obesity in children and adolescents has been rising
worldwide [1–5]. In the Netherlands, the upward trend
of severe childhood obesity resulted in a seven-fold in-
crease in the prevalence between 1980 and 2010. It was
estimated that in 2010 the prevalence was 0.56 % (which
corresponds to approximately 18 500 children and ado-
lescents in the country) [6].
Childhood obesity increases the risk of cardiometa-
bolic risk factors such as hyperlipidemia, hypertension
and diabetes mellitus type 2, as well as respiratory and
musculoskeletal conditions and liver abnormalities [7, 8].
Previous studies have shown that 62-80 % of severely
obese children and adolescents have at least one cardio-
metabolic risk factor in addition to being severely obese
[9, 10]. Moreover, (severe) obesity has a negative impact
on psychosocial health [11–14]. Severely obese children
reported to have a similar quality of life as children diag-
nosed with cancer [15]. Furthermore, there is a high
probability that childhood obesity tracks into adulthood
leading to health problems later in life [16, 17].
Research shows that obesity treatment should incorp-
orate a combination of changes in diet and physical ac-
tivity, and needs to be family-based [18–22]. Several
studies have shown that obesity treatment can lead to
weight loss in obese children and adolescents, and that
this may reduce the serious immediate and long-term
burden on physical and psychosocial health for these
obese individuals and society as a whole [23–25]. Re-
search in severely obese children and adolescents is rela-
tively rare; most studies included children with lesser
degrees of obesity. Evidence suggests that ambulatory
obesity treatment for severely obese children and adoles-
cents is insufficiently effective in the long-term and that
more intensive treatment in specialized centers is
needed [22, 26–28].
Currently the treatment center “Heideheuvel” is the only
specialized childhood obesity center in the Netherlands
that offers treatment for severely obese children and ado-
lescents. Their intensive one-year lifestyle treatment was
modeled after the treatment programme developed by
Braet et al. [29] and originally included a six-month in-
patient period. This treatment proved to be more effective
in improving SDS-BMI and cardiometabolic risk factors
than ambulatory obesity treatment [30]. However, an
inpatient period of six months is expensive and poses
a considerable burden on both the participants and
their families. Therefore, a modified treatment was
developed with a two-month inpatient period [31].
The aim of this study was to evaluate the effective-
ness of two intensive one-year lifestyle treatments
with varying inpatient periods (i.e. two months vs. six
months) for severely obese children and adolescents
with regard to SDS-BMI and cardiometabolic risk
factors such as SDS-waist circumference, systolic- and
diastolic blood pressure, and blood measurements dir-
ectly after treatment.
Methods
Study design and population
This study was designed as a randomized controlled trial
with two active treatment groups receiving a one-year
treatment programme which included a two months in-
patient part in one group and six months inpatient part
in the other group. There was also a waiting list con-
trolgroup. This paper reports on the effectiveness of the
two treatments directly after one year of treatment. The
Medical Ethics Committee of the VU University Medical
Center (Amsterdam, the Netherlands) approved the
study protocol. Prior to randomization, written informed
consent was obtained from both the participants and
their parents/caregivers. Details of the study have been
described elsewhere [31].
The study population consisted of 80 participants
(8–19 years) with severe obesity. All participants were
referred to a specialized childhood obesity center by
their local pediatrician after insufficient response to ambu-
latory obesity treatment. Severe obesity was defined as
a SDS-BMI ≥ 3.0 (99.9th age- and sex-specific per-
centile of BMI in the fourth Dutch nationwide growth
study of 1997), or a SDS-BMI ≥ 2.3 (99th age- and
sex-specific percentile of BMI in the fourth Dutch
nationwide growth study of 1997) in combination
with obesity-related comorbidity. Participants were ex-
cluded from the study if they had syndromal or
chromosomal determined obesity; obesity caused by
endocrine abnormalities or medicine use; psychiatric
problems; an IQ below 75 or if their parents/care-
givers were not willing or able to participate in the
treatment and/or study [31].
Intervention conditions
Both groups received an intensive one-year lifestyle
treatment with either an inpatient period of two months
(short-stay group) or six months (long-stay group). Dur-
ing weekdays, the short-stay group participated in a two-
month inpatient treatment, followed by biweekly return
visits of two days during the next four months, then
followed by six monthly return visits of two days. The
long-stay group participated in a six-month inpatient
treatment during weekdays, followed by six monthly re-
turn visits of two days. The treatment focused on nutri-
tion, physical activity and behavior change and required
active participation of the parents/caregivers. Treatment
was delivered at a specialized childhood obesity center,
Heideheuvel, in the Netherlands. A more detailed
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description of the content, frequency and intensity of
the treatment can be found elsewhere [31].
Randomization and blinding
The primary researcher, who was not blinded to treat-
ment allocation, randomized all participants to the
short-stay (40 participants) and long-stay group (40
participants) using a table of random numbers [32, 33].
Because it was logistically not possible to provide treat-
ment to all participants at the same time, a group of 20
participants was randomized to a one-year waiting-list
group, after which they were randomly allocated to one
of the treatment groups. Four participants dropped out
of the study while being in the waiting-list group, leading
to a waiting-list group of 16 participants. Four additional
participants were recruited to replace the four partici-
pants who dropped out of the study to ensure a study
population of 80 participants.
Because of the nature of the treatment, participants,
their parents/caregivers and healthcare professionals
could not be blinded to the treatment.
Measurements
Demographic characteristics included ethnicity, educa-
tional level, socio economic status (SES) and household
situation [31].
Outcome measures were collected at baseline and six
and 12 months of follow-up. SDS-BMI was the primary
outcome in this study and cardiometabolic risk factors
(i.e. SDS-waist circumference, systolic- and diastolic
blood pressure, and blood measurements) the secondary
outcomes.
BMI was calculated as weight/height2 (kg/m2). The de-
gree of overweight was quantified using Cole's least mean
square method, which normalizes the BMI's skewed distri-
bution and expresses BMI as SDS-BMI [34]. SDS-BMI
was calculated with the Growth Analyser [35] using the
fourth Dutch nationwide growth study of 1997 as
reference.
Waist circumference was measured with a tape
measure with an accuracy of 1 mm. SDS- waist cir-
cumference was calculated with the Growth Analyser
[35] using the fourth Dutch nationwide growth study
of 1997 as reference.
Blood pressure was measured three times in sitting
position after sitting still for at least 5 min. For the ana-
lyses, the averages of the three systolic blood pressure
and diastolic blood pressure readings were used.
Blood measurements included fasting insulin, 2h-
insulin, fasting glucose, 2h-glucose, HDL-cholesterol, tri-
glycerides and homeostasis model assessment for insulin
resistance (HOMA-IR) after an overnight fast [36].
Statistical analyses
The sample size was calculated to detect a 0.5 SDS-BMI
difference between the two groups after one year of
treatment which is considered a clinically meaningful ef-
fect size [37]. Based on a Power of 80 % and a two-tailed
significance level of 5 %, two groups of 40 participants
were needed [31].
Analyses were performed according to the intention-
to-treat principle. Baseline characteristics were com-
pared between the two treatment groups. Independent
Student’s t-tests were used for continuous variables
and Chi-square tests for categorical variables using
IBM SPSS Statistics for Windows, Version 21 (SPSS
21) [38]. Statistical significance was set at a two-sided
P-value < 0.05.
To evaluate differences in the course of the pri-
mary- and secondary outcomes over time between the
two treatment groups, Generalized Estimating Equa-
tions (GEE) were performed [39]. GEE were used to
adjust for the correlation between repeated measures
obtained in the same participant. In all models, an
exchangeable correlation structure was specified and
adjustment for baseline values was applied to assess
the actual effects of treatment on the primary- and
secondary outcomes independent of differences in
baseline values [39]. To evaluate the effects of the
two treatment groups at different time points specific-
ally (i.e. between baseline and six months follow-up
and between six- and 12 months follow-up, respect-
ively), time was treated as a categorical variable ac-
cording to the common approach described earlier by
Fitzmaurice et al. [40].
For each outcome, two types of analyses were per-
formed: 1) crude analyses which were only adjusted for
baseline values and 2) analyses which were adjusted for
baseline values and additional covariates.
Covariates were selected by first assessing them using a
forward approach and were considered relevant when the
treatment effect changed with 10 % or more after inclu-
sion of the covariate [41]. All covariates were also tested
for possible effect modification and if the interaction term
was statistically significant (i.e. a P-value ≤ 0.05), stratified
models were presented.
Additional analyses
To evaluate the effectiveness of the two treatments in
comparison with the waiting-list group in the course of
the primary- and secondary outcomes over time, GEE
were performed as well [39].
In the per protocol analysis, only participants who
took part in at least 75 % of the treatment sessions were
included. In the complete case analysis, only participants
with complete follow-up on the primary outcome SDS-
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BMI (baseline, six and 12 months) were included. In
both the per protocol and complete case analyses, the




In total, 169 participants were referred to Heideheuvel
by their local pediatrician after insufficient response
to ambulatory obesity treatment. Of them, 89 were
excluded based on either a decision made by the staff
of Heideheuvel (N = 46) or by the family (N = 43).
This left 80 participants to be included in the study
(Fig. 1).
At baseline, no relevant differences were found between
the two treatment groups (Table 1). Sixty-eight partici-
pants (85 %) completed the treatment programme. Of
these 68 participants, 61 participants (76 %) took part in
at least 75 % of the treatment sessions and were consid-
ered as per protocol participants. Complete follow-up on
the primary outcome SDS-BMI was obtained from 37
short-stay and 30 long-stay group participants (84 %). Per
protocol and not per protocol participants, and
participants with and without complete follow-up did not




Mean (SD) SDS-BMI was 3.4 (0.4) in both treatment
groups at the start of the treatment. The course of SDS-
BMI over time is graphically presented in Fig. 2. SDS-
BMI decreased statistically significantly in the first six
months in both groups. Participants were on average
able to maintain this weight-loss during the second half
year of treatment. SDS-BMI after 12 months of treat-
ment was statistically significantly lower compared with
baseline (mean difference (SD) 0.33 (0.48) in the short-
stay and 0.52 (0.49) in the long-stay group). This de-
crease in SDS-BMI corresponds to an average (SD)
weight-loss of 8.1 (14.3) kg in the short-stay and 12.6
(13.6) kg in the long-stay group.
Table 2 shows the crude and adjusted results of the
GEE. Sex, ethnicity and socio economic status were in-
cluded as covariates in the adjusted analyses. After six
months of treatment, SDS-BMI of participants in the
Fig. 1 Flow-diagram of participants. A one-year waiting-list group of 20 participants was involved. Four participants dropped out of the study
while being in the waiting-list group, leading to a waiting-list group of 16 participants
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short-stay group was higher compared with the long-
stay group (adjusted models β = 0.23, 95 % CI 0.09;
0.36). However, after one year of treatment, there was no
statistically significant difference in SDS-BMI any
more between the two treatment groups (adjusted
models β = 0.15, 95 % CI −0.06; 0.35).
Secondary outcomes
Statistically significant improvements were seen after
one year of treatment compared with baseline in both
treatment groups in SDS-waist circumference, diastolic
blood pressure and HDL-cholesterol. In the short-stay
group, systolic blood pressure improved statistically sig-
nificantly in comparison with baseline as well.
In the crude and adjusted GEE, no statistically signifi-
cantly differences in secondary outcomes between the
short-stay and long-stay groups were found at any point
in time (Table 2).
Analyses stratified by sex
Primary outcome
Sex was identified as an effect modifier. The course of
SDS-BMI over time for boys and girls in the short-stay
group followed the same course as described under the
intention-to-treat analyses. However, in the long-stay
group, SDS-BMI in boys decreased even further in the
second six months of treatment, whereas girls showed
an increase in SDS-BMI.
Results of the crude and adjusted GEE stratified by sex
are reported in Tables 3 (boys) and 4 (girls). Only for
girls, SDS-BMI of participants in the short-stay group
was higher compared with the long-stay group after six
Fig. 2 SDS-BMI for the short-stay and long-stay and waiting-list
group during 12 months of follow-up according to the intention-to-
treat principle. Error Bars indicate SE
Table 1 Baseline characteristics of the study population
Total Short-stay group Long-stay group
N = 80 N = 40 N = 40
Age (years) [mean (SD)] 14.8 (2.3) 14.5 (2.4) 15.0 (2.2)
Female [n (%)] 53 (66.3) 28 (70.0) 25 (62.5)
Ethnicities [% of total]
Western 61.5 69.2 53.8
Non-Western 38.5 30.8 46.2
Educational level of the parents/caregivers [% of total]a
Low 38.7 38.5 38.9
Medium/intermediate 42.7 43.6 41.7
High 18.7 17.9 19.4
SES [% of total]
Below average 65.8 59.5 71.8
Above average 34.2 40.5 28.2
Household situation [% of total]
Married/living together 55.0 62.5 47.5
Divorced 33.8 32.5 35.0
One parent family(mother) 7.5 2.5 12.5
Other situation 3.8 2.5 5.0
SDS-BMI [mean (SD)] 3.4 (0.39) 3.4 (0.39) 3.4 (0.39)
The short-stay group participated in a two-month intensive inpatient treatment during weekdays, followed by biweekly return visits of 2 days during the next
4 months, then followed by six monthly return visits of 2 days. The long-stay group participated in a six-month intensive inpatient treatment during weekdays,
followed by six monthly return visits of 2 days
Abbreviations: SD standard deviation, SDS-BMI standard deviation of body mass index, SES socio economic status
aEducational level was classified according to the definition of Statistics Netherlands (http://www.cbs.nl)
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Table 2 Effects on outcomes after six and 12 months of follow-up for both treatment groups according to the intention-to-treat
principle
Short-stay Long-stay Crude Adjusted
Mean (SD) Mean (SD) Beta (95 % CI) Beta (95 % CI)
Primary outcome measure
SDS-BMI
Baseline 3.4 (0.4) 3.4 (0.4)
6-months 3.1 (0.5) 2.9 (0.6) 0.22 (0.09; 0.35) 0.23 (0.09; 0.36)
12-months 3.1 (0.6) 2.9 (0.7) 0.18 (−0.03; 0.40) 0.18 (−0.04; 0.40)
Overall effecta 0.10 (−0.11; 0.31) 0.15 (−0.06; 0.35)
Secondary outcomes
SDS-waist circumference
Baseline 3.2 (0.4) 3.1 (0.4)
6-months 2.7 (0.5) 2.5 (0.5) 0.13 (−0.03; 0.30) 0.12 (−0.05; 0.30)
12-months 2.7 (0.7) 2.5 (0.7) 0.08 (−0.18; 0.34) 0.02 (−0.23; 0.27)
Overall effecta 0.14 (−0.07; 0.35) 0.15 (−0.07; 0.37)
Systolic blood pressure (mmHg)
Baseline 122.7 (12.3) 121.1 (13.4)
6-months 117.1 (13.9) 116.7 (13.4) −0.63 (−4.73; 3.48) 0.17 (−3.98; 4.33)
12-months 118.4 (11.2) 120.0 (15.3) −2.84 (−7.27; 1.60) −2.25 (−6.95; 2.45)
Overall effecta 0.59 (−4.65; 5.82) 0.44 (−4.86; 5.75)
Diastolic blood pressure (mmHg)
Baseline 75.7 (9.9) 78.0 (12.3)
6-months 68.5 (7.9) 68.3 (11.2) 1.49 (−2.04; 5.02) 0.47 (−3.17; 4.11)
12-months 68.6 (8.1) 67.1 (12.0) 3.02 (−0.72; 6.76) 2.35 (−1.64; 6.34)
Overall effecta −0.42 (−4.40, 3.56) −1.21 (−5.21, 2.80)
Fasting insulin (μU/L)
Baseline 13.8 (9.3) 14.6 (9,5)
6-months 11.9 (9.3) 12.9 (10.8) −0.98 (−4.50; 2.55) −1.41 (−5.20; 2.39)
12-months 11.7 (9.1) 14.1 (10.1) −1.27 (−4.25; 1.70) −2.15 (−5.39; 1.09)
Overall effecta −1.10 (−3.60; 1.40) −2.30 (−5.75; 1.16)
2 h-insulin (μU/L)
Baseline 70.7 (49.9) 60.8 (36.8)
6-months 63.0 (56.9) 52.4 (37.7) 1.16 (−17.21; 19.52) −0.80 (−19.82; 18.22)
12-months 67.9 (47.4) 65.3 (54.5) −0.54 (−23.38; 22.48) −2.89 (−26.49; 20.71)
Overall effecta 0.65 (−15.50; 16.80) 1.86 (−13.59; 17.31)
Fasting glucose (mmol/L)
Baseline 4.7 (0.4) 4.7 (0.3)
6-months 4.8 (0.4) 4.8 (0.3) 0.03 (−0.11; 0.16) 0.02 (−0.13; 0.16)
12-months 4.8 (0.4) 4.9 (0.3) −0.06 (−0.19; 0.08) −0.01 (−0.13; 0.12)
Overall effecta −0.04 (−0.16; 0.08) −0.02 (−0.14; 0.10)
2 h-glucose (mmol/L)
Baseline 6.0 (1.2) 5.6 (1.1)
6-months 5.4 (1.1) 5.1 (1.0) −0.02 (−0.47; 0.42) −0.02 (−0.51; 0.47)
12-months 5.8 (1.1) 5.3 (1.4) 0.32 (−0.24; 0.87) 0.29 (−0.32; 0.89)
Overall effecta 0.35 (−0.06; 0.77) 0.35 (−0.07; 0.76)
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months of treatment, (adjusted models β = 0.20, 95 % CI
0.07; 0.33). After one year of treatment, there was no
statistically significant difference in SDS-BMI between
the two treatment groups for either sex.
Secondary outcomes
Analyses stratified by sex showed statistically significant
improvements in SDS-waist circumference, diastolic
blood pressure and HDL-cholesterol after one year of
treatment compared with baseline.
For girls there was a statistically significant difference
in HDL-cholesterol between the short-stay and long-stay
group after six months of follow-up (adjusted models
β = 0.11, 95 % CI 0.03; 0.19). There were no statisti-
cally significant differences in secondary outcomes be-
tween the treatment groups after one year of treatment
after stratification by sex as demonstrated by the crude
and adjusted GEE (Tables 3 and 4).
Additional analyses
Waiting-list group
During the waiting list period, mean (SD) SDS-BMI in-
creased from 3.55 (0.31) to 3.61 (0.53) in the year prior
to the start of treatment, but this was not statistically
significant (Fig. 2).
The crude and adjusted GEE showed that the SDS-
BMI of participants in the short-stay group and long-
stay group was statistically significantly lower (0.32, 95 %
CI −0.43; −0.21 and 0.49, 95 % CI −0.62; −0.36,
respectively) after one year of treatment compared with
the waiting-list group.
There was a statistically significant improvement in
SDS-waist circumference, systolic- and diastolic blood
pressure, fasting insulin, HDL-cholesterol, and HOMA-
IR after one year of treatment in the two treatments
groups in comparison with the waiting-list group (data
not shown).
Per protocol and complete case analyses In the add-
itional analyses the course of SDS-BMI over time
followed the same course in the per protocol analyses as
in the intention-to-treat analyses.
After one year of treatment, there was no statistically
significant difference in SDS-BMI between the two treat-
ment groups (data not shown).
There were statistically significant improvements in
both treatment groups in SDS-waist circumference, dia-
stolic blood pressure and HDL-cholesterol after one year
of treatment compared with baseline. In the short-stay
group, systolic blood pressure improved statistically sig-
nificantly in comparison with baseline as well. Addition-
ally, in the per protocol analyses, in the short-stay group
also fasting insulin, 2h-glucose and HOMA-IR improved
statistically significantly.
In the complete case analyses, after one year of treat-
ment there were no statistically significant differences
between the treatment groups in any of the secondary
outcomes; in the per protocol analyses there was a
Table 2 Effects on outcomes after six and 12 months of follow-up for both treatment groups according to the intention-to-treat
principle (Continued)
HDL-cholesterol (mmol/L)
Baseline 1.1 (0.3) 1.0 (0.2)
6-months 1.2 (0.3) 1.1 (0.2) 0.04 (−0.02; 0.11) 0.04 (−0.03; 0.11)
12-months 1.2 (0.3) 1.2 (0.3) −0.07 (−0.17; 0.04) −0.04 (−0.14; 0.07)
Overall effecta 0.07 (−0.03; 0.17) 0.09 (−0.02; 0.20)
Triglycerides (mmol/L)
Baseline 1.0 (0.6) 1.0 (0.5)
6-months 1.1 (1.0) 1.0 (0.5) 0.09 (−0.14, 0.31) 0.04 (−0.15, 0.22)
12-months 1.2 (0.9) 1.1 (0.7) 0.09 (−0.18, 0.35) 0.04 (−0.22, 0.29)
Overall effecta 0.09 (−0.18, 0.37) 0.06 (−0.17, 0.29)
HOMA-IR
Baseline 2.9 (2.0) 3.1 (2.1)
6-months 2.5 (2.0) 2.8 (2.4) −0.17 (−0.96; 0.61) −0.26 (−1.11; 0.59)
12-months 2.5 (2.0) 3.1 (2.4) −0.33 (−1.02, 0.37) −0.44 (−1.17, 0.30)
Overall effecta −0.31 (−1.11; 0.49) −0.52 (−1.28; 0.25)
Adjusted models corrected for baseline, sex, ethnicity, and economic status
Abbreviations: CI confidence interval, SD standard deviation, SDS-BMI standard deviation of body mass index, SDS-waist circumferencestandard deviation of waist
circumference, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment for insulin resistance
aOverall effect can be interpreted as the average difference over time between the two treatment groups
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Table 3 Effects on outcomes after six and 12 months of follow-up for both treatment groups according to the intention-to-treat
principle, boys only
Short-stay Long-stay Crude Adjusted
Mean (SD) Mean (SD) Beta (95 % CI) Beta (95 % CI)
Primary outcome measure
SDS-BMI
Baseline 3.7 (0.4) 3.7 (0.4)
6-months 3.4 (0.6) 3.1 (0.7) 0.25 (−0.03; 0.52) 0.23 (−0.07; 0.53)
12-months 3.4 (0.7) 2.9 (0.8) 0.34 (−0.09; 0.77) 0.31 (−0.14; 0.76)
Overall effecta 0.25 (−0.15; 0.64) 0.26 (−0.15; 0.67)
Secondary outcomes
SDS-waist circumference
Baseline 3.5 (0.4) 3.3 (0.3)
6-months 3.0 (0.7) 2.6 (0.6) 0.10 (−0.35; 0.55) 0.05 (−0.39; 0.48)
12-months 3.0 (1.0) 2.4 (0.9) 0.12 (−0.48; 0.72) 0.01 (−0.57; 0.60)
Overall effecta 0.40 (−0.03; 0.83) 0.40 (−0.06; 0.86)
Systolic blood pressure (mmHg)
Baseline 124.3 (15.0) 125.1 (14.0)
6-months 122.0 (18.7) 120.2 (11.9) 3.34 (−5.35; 12.03) 4.31 (−3.56; 12.19)
12-months 122.1 (12.3) 123.3 (14.4) −1.46 (−9.12; 6.20) 0.45 (−6.74; 7.64)
Overall effecta 0.52 (−9.22; 10.25) 2.04 (−8.27; 12.36)
Diastolic blood pressure (mmHg)
Baseline 77.7 (11.0) 80.9 (9.2)
6-months 64.4 (8.0) 68.2 (10.0) −1.61 (−8.46; 5.24) −2.91 (−9.17; 3.35)
12-months 69.4 (8.3) 66.5 (11.7) 5.28 (−0.21; 10.76) 3.86 (−2.23; 9.94)
Overall effecta −0.73 (−7.66, 4.06) −1.80 (−7.66, 4.06)
Fasting insulin (μU/L)
Baseline 15.3 (7.7) 16.2 (13.2)
6-months 12.4 (12.6) 11.8 (11.0) 0.78 (−4.44; 6.00) 0.73 (−4.54; 6.00)
12-months 11.1 (5.8) 14.4 (13.8) −0.82 (−4.84; 3.20) −1.15 (−5.06; 2.76)
Overall effecta −0.58 (−7.69; 6.53) 0.14 (−6.93; 7.22)
2 h-insulin (μU/L)
Baseline 75.4 (50.2) 53.3 (34.6)
6-months 64.5 (68.2) 38.6 (20.2) 13.21 (−21.43; 47.84) 14.30 (−18.69; 47.29)
12-months 65.1 (41.3) 62.7 (33.8) 2.81 (−14.94; 20.56) 3.47 (−16.01; 22.96)
Overall effecta 21.31 (−7.19; 49.81) 22.60 (−5.09; 50.30)
Fasting glucose (mmol/L)
Baseline 4.6 (0.2) 4.8 (0.4)
6-months 4.8 (0.3) 4.7 (0.3) 0.14 (−0.05; 0.34) 0.14 (−0.05; 0.34)
12-months 4.7 (0.3) 5.0 (0.2) −0.16 (−0.36; 0.04) −0.17 (−0.36; 0.02)
Overall effecta −0.14 (−0.31; 0.03) −0.10 (−0.25; 0.06)
2 h-glucose (mmol/L)
Baseline 6.3 (1.1) 5.7 (0.9)
6-months 5.7 (1.5) 4.9 (0.9) 0.43 (−0.47; 1.33) 0.48 (−0.39; 1.34)
12-months 5.6 (0.9) 6.0 (1.1) −0.40 (−1.06; 0.27) −0.43 (−1.14; 0.29)
Overall effecta 0.42 (−0.26; 1.10) 0.49 (−0.25; 1.23)
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statistically significant difference between the treatment
groups in HDL-cholesterol (data not shown).
Discussion
In this randomized controlled trial, two intensive life-
style treatments for severely obese children and adoles-
cents with varying inpatient periods (two or six months)
were compared. Both treatments showed statistically sig-
nificant improvements in SDS-BMI and cardiometabolic
risk factors after treatment compared with baseline.
However, after one year of treatment, there were no
statistically significant differences in SDS-BMI or cardio-
metabolic risk factors between the two treatment groups.
In an additional analysis, it was shown that SDS-BMI
and cardiometabolic risk factors of participants in both
treatment groups improved statistically significantly after
one year of treatment compared with participants in a
waiting-list controlgroup.
The decreases in SDS-BMI that were observed in this
study correspond to an average (SD) weight-loss of 8.1
(14.3) kg in the short-stay and 12.6 (13.6) kg in the long-
stay group, which is generally considered a clinically
relevant improvement [37]. The children in this study
were referred to the specialized childhood obesity center
because they did not respond to treatment in an ambu-
latory setting. This study shows that even in this
children considerable weight loss can and improvement
in cardiovascular risk be achieved.
Many of the participants’ parents were of Non-Western
origin and had a lack of proficiency in the Dutch language
which complicated treatment in some cases due to com-
munication problems. Despite this, considerable improve-
ments in SDS-BMI were achieved. Also, a relatively high
percentage of the participants came from single-parent
families and had a low SES background which can be con-
sidered a less favorable home environment to retain
weight loss. However, our results showed that weight re-
ductions achieved after the intensive inpatient treatment
period in the first six months were on average maintained
in the second half of the year when only monthly follow-
up visits were provided [42–44].
Ambulatory obesity treatment often seems far less ef-
fective for severely obese children in comparison with
children and adolescents with a lesser degree of obesity
[26–28, 45]. Therefore, an inpatient treatment seems
more appropriate for these children and adolescents
[30]. An inpatient setting provides a more supportive en-
vironment than ambulatory obesity treatment where
children often have to deal with a less supportive home
environment every day. The large decrease in SDS-BMI
we observed might therefore be explained by the exten-
sive inpatient period in the treatments in our study. Dur-
ing the past decades in the Netherlands several studies
have evaluated the effects of treatments for children and
adolescents with (severe) obesity. Most of these studies,
however, evaluated ambulatory treatment programs and
included populations that consisted of a combination of
obese and severely obese participants. A Dutch study by
Hofsteenge et al. among severely obese children that
were on average less obese than the participants
Table 3 Effects on outcomes after six and 12 months of follow-up for both treatment groups according to the intention-to-treat
principle, boys only (Continued)
HDL-cholesterol (mmol/L)
Baseline 1.1 (0.3) 1.0 (0.2)
6-months 1.1 (0.4) 1.1 (0.2) −0.08 (−0.18; 0.13) −0.08 (−0.19; 0.03)
12-months 1.2 (0.5) 1.2 (0.4) −0.08 (−0.27; 0.11) −0.07 (−0.28; 0.15)
Overall effecta 0.05 (−0.17; 0.28) 0.08 (−0.13; 0.29)
Triglycerides (mmol/L)
Baseline 1.0 (0.5) 1.2 (0.7)
6-months 1.1 (0.7) 1.1 (0.7) 0.13 (−0.30, 0.56) 0.06 (−0.31, 0.44)
12-months 1.4 (0.9) 1.4 (0.9) −0.06 (−0.51, 0.63) −0.04 (−0.56, 0.48)
Overall effecta −0.10 (−0.56, 0.36) −0.10 (−0.52, 0.33)
HOMA-IR
Baseline 3.1 (1.5) 3.5 (3.0)
6-months 2.7 (2.7) 2.5 (2.4) 0.40 (−0.77; 1.58) 0.37 (−0.80; 1.54)
12-months 2.3 (1.2) 3.3 (3.3) −0.17 (−1.05, 0.72) −0.27 (−1.12, 0.59)
Overall effecta −0.30 (−1.87; 1.28) −0.12 (−1.68; 1.44)
Adjusted models corrected for baseline, ethnicity, and socio economic status
Abbreviations: CI confidence interval, SD standard deviation, SDS-BMI standard deviation of body mass index, SDS-waist circumference standard deviation of waist
circumference, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment for insulin resistance
aOverall effect can be interpreted as the average difference over time between the two treatment groups
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Table 4 Effects on outcomes after 6 and 12 months of follow-up for both treatment groups according to the intention-to-treat
principle, girls only
Short-stay Long-stay Crude Adjusted
Mean (SD) Mean (SD) Beta (95 % CI) Beta (95 % CI)
Primary outcome measure
SDS-BMI
Baseline 3.3 (0.3) 3.3 (0.3)
6-months 3.0 (0.5) 2.8 (0.5) 0.19 (0.06; 0.31) 0.20 (0.07; 0.33)
12-months 3.0 (0.5) 3.0 (0.6) 0.06 (−0.16; 0.28) 0.07 (−0.14; 0.28)
Overall effecta 0.08 (−0.14; 0.30) 0.06 (−0.17; 0.30)
Secondary outcomes
SDS-waist circumference
Baseline 3.0 (0.3) 3.0 (0.3)
6-months 2.6 (0.4) 2.5 (0.5) 0.10 (−0.05; 0.25) 0.10 (−0.06; 0.26)
12-months 2.6 (0.6) 2.6 (0.6) −0.03 (−0.27; 0.22) −0.07 (−0.28; 0.15)
Overall effecta 0.05 (−0.15; 0.26) −0.00 (−0.22; 0.22)
Systolic blood pressure (mmHg)
Baseline 122.0 (11.2) 118.7 (12.6)
6-months 115.2 (11.5) 114.3 (14.1) −2.25 (−6.63; 2.13) −2.39 (−6.75; 1.96)
12-months 117.3 (10.9) 117.9 (15.9) −3.71(−9.22; 1.81) −4.17 (−10.08; 1.74)
Overall effecta 1.32 (−4.84; 7.49) −0.27 (−6.22; 5.68)
Diastolic blood pressure (mmHg)
Baseline 74.8(9.5) 76.3 (13.6)
6-months 70.2 (7.5) 68.4 (12.2) 2.31 (−1.52; 6.13) 1.94 (−2.19; 6.07)
12-months 68.3 (8.3) 67.5 (12.5) 1.28 (−3.24; 5.80) 0.68 (−4.19; 5.55)
Overall effecta −0.32 (−5.57, 4.92) −0.56 (−5.86, 4.75)
Fasting insulin (μU/L)
Baseline 13.2 (10.0) 13.6 (6.4)
6-months 11.7 (7.8) 13.6 (10.9) −2.18 (−6.87; 2.51) −3.21 (−8.78; 2.37)
12-months 11.9 (10.2) 13.9 (7.2) −1.68 (−5.66; 2.30) −3.21 (−7.96; 1.55)
Overall effecta −1.42 (−5.32; 2.48) −3.68 (−6.88; 0.48)
2 h-insulin (μU/L)
Baseline 68.7 (50.5) 65.5 (38.0)
6-months 62.3 (52.9) 60.6 (43.5) −6.39 (−28.67; 15.90) −7.93 (−31.08; 15.22)
12-months 68.9 (50.4) 67.0 (65.4) −2.70 (−37.22; 31.81) −4.80 (−38.42; 28.82)
Overall effecta 0.16 (−32.31 21.64) −10.37 (−27.09; 6.36)
Fasting glucose (mmol/L)
Baseline 4.8 (0.4) 4.7 (0.2)
6-months 4.8 (0.4) 4.8 (0.4) −0.05 (−0.23; 0.12) −0.09 (−0.28; 0.10)
12-months 4.8 (0.4) 4.8 (0.3) 0.01 (−0.15; 0.17) 0.06 (−0.09; 0.22)
Overall effecta 0.01 (−0.15; 0.16) 0.02 (−0.13; 0.17)
2 h-glucose (mmol/L)
Baseline 5.9 (1.3) 5.6 (1.2)
6-months 5.2 (1.0) 5.3 (1.1) −0.26 (−0.77; 0.25) −0.23 (−0.80; 0.34)
12-months 5.8 (1.2) 4.9 (1.4) 0.73 (−0.01; 1.48) 0.71 (−0.11; 1.54)
Overall effecta 0.34 (−0.18; 0.87) 0.21 (−0.24; 0.66)
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followed in our study, showed that SDS-BMI after 18
months of treatment was statistically significantly lower
in the intervention group than in the control group.
However, this effect was only observed in obese adoles-
cents from Western origin and not in those of Non-
Western origin [46].
Another Dutch study by Vos et al. followed a group of
severely obese children and adolescents receiving ambu-
latory obesity treatment for three months [47]. Directly
after treatment, SDS-BMI had decreased and after one
year of follow-up in which 2–3 refresher sessions were
offered, SDS-BMI decreased even further [47]. The de-
crease in SDS BMI after one year was comparable to the
decrease in SDS-BMI in our study after six months after
which SDS-BMI stabilized. Only among boys in the
long-stay group we also found a further decrease in SDS
BMI in the second half year. A possible explanation for
this difference in favor of severely obese boys, could be
that puberty may contribute to a more beneficial weight
development in boys [48].
The only other study by van der Baan et al. in the
Netherlands that also evaluated treatment with an in-
patient period of six months among severely obese chil-
dren using the same inclusion criteria as our study,
showed a decrease in SDS-BMI after six months that
was comparable with our study. However, this study
showed a slight increase in SDS-BMI in the second half
year of follow-up [30]. This might be due to the fact that
there were no return visits after the six-month inpatient
period.
Research among severely obese children and adoles-
cents is relatively rare. The few studies performed in the
Netherlands and other countries show that among se-
verely obese adolescents, improvements in SDS-BMI
during obesity treatment can be maintained during
follow-up [49]. However, sustained behavior change is a
difficult and complex process. Therefore, it is important
to also have sufficient support available for parents and
children after the most intensive treatment period to
maintain learned changes. Regular return visits or re-
fresher sessions seem essential to prevent relapse.
Strengths and limitations
This study has several strengths. First, it is unique with
regard to the intensity of the treatments studied, since
most lifestyle treatments for severely obese children and
adolescents do not include an inpatient period. More-
over, although the duration of treatment was long with
one year, this did not result in a high attrition rate; only
12 participants (15 %) dropped out of treatment. Com-
pared to other studies evaluating the effects of obesity
treatment in adolescents this dropout is rather small
[46]. Because participants will go back to their home en-
vironment after treatment, it is very important that the
family of the participants is involved in the treatment.
Therefore, a second strength of this study is that not
only the participants were involved in the treatment, but
that the treatment was family-based with active parental
participation. Finally, both treatment groups were com-
pared to a waiting-list controlgroup. Therefore, this
Table 4 Effects on outcomes after 6 and 12 months of follow-up for both treatment groups according to the intention-to-treat
principle, girls only (Continued)
HDL-cholesterol (mmol/L)
Baseline 1.1 (0.2) 1.0 (0.2)
6-months 1.2 (0.2) 1.1 (0.2) 0.11 (0.03; 0.19) 0.11 (0.03; 0.19)
12-months 1.2 (0.2) 1.2 (0.3) −0.07 (−0.18; 0.05) −0.03 (−0.14; 0.09)
Overall effecta 0.08 (−0.02; 0.18) 0.10 (−0.01; 0.21)
Triglycerides (mmol/L)
Baseline 1.0 (0.6) 0.9 (0.3)
6-months 1.1 (1.1) 0.9 (0.3) −0.01 (−0.24, 0.21) −0.05 (−0.25, 0.15)
12-months 1.1 (1.0) 0.9 (0.3) 0.08 (−0.16, 0.32) 0.03 (−0.19, 0.25)
Overall effecta 0.22 (−0.09, 0.54) 0.11 (−0.13, 0.36)
HOMA-IR
Baseline 2.8 (2.3) 2.9 (1.4)
6-months 2.5 (1.7) 2.9 (2.4) −0.49 (−1.53; 0.55) −0.73 (−1.96; 0.51)
12-months 2.5 (2.2) 3.0 (1.6) −0.40 (−1.31, 0.51) −0.63 (−1.72, 0.46)
Overall effecta −0.29 (−1.13; 0.55) −0.75 (−1.46; 0.04)
Adjusted models corrected for baseline, ethnicity, and socio economic status
Abbreviations: CI confidence interval, SD standard deviation, SDS-BMI standard deviation of body mass index, SDS-waist circumference standard deviation of waist
circumference, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment for insulin resistance
aOverall effect can be interpreted as the average difference over time between the two treatment groups
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study not only gives insight into the effects of the inten-
sive treatments compared to each other, but also as
compared with a waiting-list condition during which the
children received usual care.
There are several limitations as well. The treatments
pose a high burden on the participating families. The fre-
quent visits resulted in high time investments for parents
and associated time costs. Moreover, parents/caregivers
often needed to take time off from work to participate in
treatment resulting in productivity losses. In addition,
children were placed in an environment completely new
to them and were away from their families, home, school
and friends for an extended period of time, especially in
the long-stay group. Another limitation is that, although a
waiting-list group was included, data were available for
only 16 participants as four participants in the waiting list
condition dropped out of the study. Due to practical rea-
sons, we were unable to recruit more participants into the
waiting-list group prior to treatment.
Implications
To ensure long-term maintenance of weight-loss after
intensive treatment, continuous monitoring and periodic
intensive return visits seem essential. Treatment in spe-
cialized childhood obesity centers is costly and poses a
high burden to families and care-givers, so preferably
long-term treatment is organized in the home environ-
ment making it more feasible and less expensive than
long-term treatment in specialized childhood obesity
centers. It is important that the organization and transfer
of treatment from an inpatient setting to an ambulatory
setting is prepared carefully, to ensure that participants
are not lost to follow-up and receive the right kind of con-
tinuous treatment. Special attention to attrition from the
continuous treatment in the ambulatory setting is needed.
Conclusions
No statistically significant differences in SDS-BMI were
found between the short-stay and long-stay inpatient
segments during one year of treatment. However, both
treatments resulted in statistically significant improve-
ments in comparison with baseline and were statistically
significantly more effective than a waiting list condition.
Based on these results, we recommend implementa-
tion of the short-stay treatment because of the lower
burden for the participating families and the lower costs
of treatment. However, whether this treatment should be
implemented on a wider scale depends on whether the
effects of the inpatient treatment in comparison with
usual care are sustained over a longer period of time.
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